MDCL.F Stock Overview
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MedinCell S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.98 |
| 52 Week High | €11.12 |
| 52 Week Low | €6.97 |
| Beta | 1 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDCL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 1.6% |
| 1Y | n/a | 12.5% | 26.3% |
Return vs Industry: Insufficient data to determine how MDCL.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MDCL.F performed against the US Market.
Price Volatility
| MDCL.F volatility | |
|---|---|
| MDCL.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDCL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MDCL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 131 | Christophe Douat | www.medincell.com |
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company’s products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
MedinCell S.A. Fundamentals Summary
| MDCL.F fundamental statistics | |
|---|---|
| Market cap | US$177.47m |
| Earnings (TTM) | -US$33.82m |
| Revenue (TTM) | US$14.43m |
12.3x
P/S Ratio-5.2x
P/E RatioIs MDCL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDCL.F income statement (TTM) | |
|---|---|
| Revenue | €13.66m |
| Cost of Revenue | €0 |
| Gross Profit | €13.66m |
| Other Expenses | €45.67m |
| Earnings | -€32.01m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Dec 06, 2023
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 100.00% |
| Net Profit Margin | -234.42% |
| Debt/Equity Ratio | -128.9% |
How did MDCL.F perform over the long term?
See historical performance and comparison